Can Finerenone Alter Glomerular Disease Trajectory? - Takeaways - MDSpire

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 4 min

Share

  • 1

    The FIND-CKD trial included 903 participants with glomerular diseases, assessing the effects of finerenone versus placebo.

  • 2

    Finerenone reduced the eGFR decline by 1.22 mL/min/1.73 m² per year after 3 months compared to placebo.

  • 3

    In the immunoglobulin A nephropathy subgroup, finerenone decreased urinary albumin-to-creatinine ratio by 47%.

  • 4

    Serious adverse events were similar between finerenone (20%) and placebo (21%) groups, with low rates of hyperkalemia.

  • 5

    The study faced limitations, including reliance on investigator-reported diagnoses and lack of biopsy confirmation for many participants.

Original Source(s)

Can Finerenone Alter Glomerular Disease Trajectory?

  • by Kathryn Wighton

  • June 5, 2026

Related Content

The role of albumin–globulin ratio in peripheral arterial disease among hypertensive adults: evidence from a large-scale multicenter study

Congo Ebola Outbreak Strains Care Delivery

“We live with fear in our stomachs"

Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort study